Tag: Michel Pairet
Boehringer Ingelheim expands oncology portfolio with T3 Pharma acquisition
Boehringer Ingelheim announced its acquisition of T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech company specializing in immuno-oncology, for up to 450 million CHF. T3 ... Read More
Boehringer Ingelheim to acquire NBE-Therapeutics for €1.1bn
German pharma company Boehringer Ingelheim has signed a deal worth €1.18 billion to acquire NBE-Therapeutics, a clinical-stage Switzerland-based biotech company, focused on developing antibody-drug conjugates ... Read More
Boehringer Ingelheim acquires Swiss biotech company AMAL Therapeutics
Boehringer Ingelheim acquisition of AMAL Therapeutics : German pharma company Boehringer Ingelheim has acquired Swiss biotech company AMAL Therapeutics for up to EUR325 million, as ... Read More